Affordable Access

Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.

Authors
  • Grese, T A
  • Pennington, L D
  • Sluka, J P
  • Adrian, M D
  • Cole, H W
  • Fuson, T R
  • Magee, D E
  • Phillips, D L
  • Rowley, E R
  • Shetler, P K
  • Short, L L
  • Venugopalan, M
  • Yang, N N
  • Sato, M
  • Glasebrook, A L
  • Bryant, H U
Type
Published Article
Journal
Journal of medicinal chemistry
Publication Date
Apr 09, 1998
Volume
41
Issue
8
Pages
1272–1283
Identifiers
PMID: 9548817
Source
Medline
License
Unknown

Abstract

The 2-arylbenzothiophene raloxifene, 1, is a selective estrogen receptor modulator (SERM) which is currently under clinical evaluation for the prevention and treatment of postmenopausal osteoporosis. In vivo structure-activity relationships and molecular modeling studies have indicated that the orientation of the basic amine-containing side chain of 1, relative to the stilbene plane, is an important discriminating factor for the maintenance of tissue selectivity. We have constructed a series of analogues of 1 in which this side chain is held in an orientation which is orthogonal to the stilbene plane, similar to the low-energy conformation predicted for raloxifene. Herein, we report on the synthesis of these compounds and on their activity in a series of in vitro and in vivo biological assays reflective of the SERM profile. In particular, we describe their ability to (1) bind the estrogen receptor, (2) antagonize estrogen-stimulated proliferation of MCF-7 cells in vitro, (3) stimulate TGF-beta3 gene expression in cell culture, (4) inhibit the uterine effects of ethynyl estradiol in immature rats, and (5) potently reduce serum cholesterol and protect against osteopenia in ovariectomized (OVX) rats without estrogen-like stimulation of uterine tissue. These data demonstrate that one of these compounds, LY357489,4, is among the most potent SERMs described to date with in vivo efficacy on bone and cholesterol metabolism in OVX rats at doses as low as 0.01 mg/kg/d.

Report this publication

Statistics

Seen <100 times